5. Administration of drug products with evident effect on immune system for previous 3 months prior screening (including corticosteroids. Remark: Topical agents (e.g. for rash treatment), inhalation aerosols (e.g. for treatment of broncho-obstructive diseases), eye drops and agents for local administration (e.g. to joint cavity) is allowed
6. Participation in other clinical studies or administration of study products for 30 days prior screening, or persisting adverse reactions of the study product
7. Patients that have not taken CBLB502
8. Patients with hypersensitivity/allergy to CBLB502 or excipients of the drug product; NSAID (including ibuprofen)
9. Pregnant or lactating women
10. History of salmonellosis
11. Body mass \> 88 kg; no obesity which means BMI in the range 18.5-25 kg/m2 for women and 22-27 kg/m2 for men
12. Men and women of childbearing age which do agree to use double contraception method, oral contraception or abstain from sex contacts throughout the study
13. Alcohol abuse, drug abuse and any other medical, psychological and social reasons which may, in accordance with the investigator, affect patient's participation in the study, may prevent adequate assessment of the study results
14. Any conditions which are unstable or may endanger patient's safety and/or affect his/her adherence to the investigator instruction
15. Any patient is not able or willing to cooperate with the investigator
Clareo Health | Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer
